Posted on

brazil cbd gummies

Our story begins in 2012 when our team owned a medical cannabis dispensary offering a variety of cannabis products. Daily customers would ask if we carried any CBD products, and sadly, we had to say no. Though we searched for quality CBD to provide our customers, we could not find one product that met our standards. Realizing this was an industry in need of regulation we decided to create our own CBD product. This is the moment Revivid was born.

The Agricultural Act of 2014 federally legalized industrial hemp opening a door for us to create our own vertically integrated CBD supply chain. This way we could control every part of our growing and refining process to deliver the finest CBD on the market.

Through proprietary hemp genetics, food-grade extraction methods, strict quality control guidelines, and ethical standards we promise to provide you with the finest CBD on the market.

Clinical trials with cannabidiol (CBD) in healthy volunteers, isomniacs, and epileptic patients conducted in the authors’ laboratory from 1972 up to the present are reviewed. Acute doses of cannabidiol ranging from 10 to 600 mg and chronic administration of 10 mg for 20 days or 3 mg/kg/day for 30 days did not induce psychologic or physical symptoms suggestive of psychotropic or toxic effects; however, several volunteers complained of somnolence. Complementary laboratory tests (EKG, blood pressure, and blood and urine analysis) revealed no sign of toxicity. Doses of 40, 80, and 160 mg cannabidiol were compared to placebo and 5 mg nitrazepam in 15 insomniac volunteers. Subjects receiving 160 mg cannabidiol reported having slept significantly more than those receiving placebo; the volunteers also reported significantly less dream recall; with the three doses of cannabidiol than with placebo. Fifteen patients suffering from secondary generalized epilepsy refractory to known antiepileptic drugs received either 200 to 300 mg cannabidiol daily or placebo for as long as 4.5 months. Seven out of the eight epileptics receiving cannabidiol had improvement of their disease state, whereas only one placebo patient improved.